Table 1.

Antiproliferative activity of NXD30001 in human schwannoma and meningioma primary cultures

Primary cellsGI50 (nmol/L)Clinical statusAgeNF2 gene mutationPredicted effectLOH
HEI193 (immortalized)14.9NF2c.1575-1G>Ar.1575_1737delHemizygous loss of Ch 22
Vestibular schwannoma-1113.4Sporadic60c.888delTp.Ile296fsN.A.
Vestibular schwannoma-550.0Sporadic48c.161_162delTGp.Lys54fsN.A.
Vestibular schwannoma-9117.5Sporadic45c.592C>Tp.Arg198*N.A.
Vestibular schwannoma-11130.0NF223c.447+1G>Tp.Tyr150_Arg172delHemizygous loss of NF2
Vestibular schwannoma-13110.2Sporadic46c.115-5_115-51del47r.?N.A.
Vestibular schwannoma-1763.5Sporadic13c.478delCp.Arg160fsHemizygous loss of Ch 22
Spinal schwannoma-118.6NF2a22c.1445delCinsTGGp.Pro482fsHomologous duplication
Spinal meningioma-263.4NF2a22c.1445delCinsTGGp.Pro482fsHomologous duplication
Cranial meningioma-31050.0NF253NF2 mutation not identifiedNormalHemizygous loss of Ch 22
Cranial meningioma-4734.0NF239c.1021C>Tp.Arg341*Hemizygous loss of NF2

NOTE: Classification of sporadic or NF2-associated status was based on the diagnoses from referring physicians. Mutations are listed with the numbering of bases showing alterations relative to the cDNA sequence with the initiator ATG beginning at base = 1. GI50 is determined for 72 hours drug treatment.

Abbreviations: c., cDNA; r., mRNA; p., protein sequences; N.A., not analyzed.

  • aThe tumors were 2 spinal cord tumors from the same patient.